# US 2019/0314277 A1 · Methods for Treating Lung Disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0314277 A1
- Document ID: US20190314277A1
- Status: Published application
- Kind: A1
- Application number: 16/444,299
- Filed: 2019-06-18
- Published: 2019-10-17
- Earliest claimed: 2017-06-14
- Assignees: Crititech, Inc.
- Applicants: Crititech, Inc.
- Inventors: Michael Baltezor; Matthew McClorey; William Johnston; Gere S. diZerega; James Verco
- Web page: https://patentgrep.com/patent/US20190314277A1

## CPC

- A61K 9/0078: {for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions}
- A61K 9/10: Dispersions; Emulsions
- A61K 9/14: Particulate form, e.g. powders, {Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles (microspheres A61K9/16; microcapsules A61K9/50; nanocapsules, nanoparticles of the matrix type A61K9/51)}
- A61K 9/1611: {Inorganic compounds}
- A61K 9/1623: {Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules}
- A61K 31/337: having four-membered rings, e.g. taxol
- A61K 47/02: Inorganic compounds
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed herein are compositions and methods for treating lung disorders including lung tumors by pulmonary administration of compositions comprising taxane particles such as docetaxel or paclitaxel particles.

## Claims

### Claim 1

A method for treating a lung tumor, comprising pulmonary administration to a subject with a lung tumor of an amount effective of a composition comprising taxane particles to treat the lung tumor, wherein the taxane particles comprise at least 95% of the taxane and have a mean particle size (number) of between 0.1 μm and 5 μm, wherein the taxane particles have a specific surface area (SSA) of at least 12 m2/g, wherein the taxane particles are present in a suspension comprising the taxane particles and a pharmaceutically acceptable carrier, wherein the suspension is aerosolized for administration, wherein the pulmonary administration comprises nebulization, and wherein the nebulization results in pulmonary delivery to the subject of aerosol droplets of the taxane particles suspension.

### Claim 2

(canceled)

### Claim 3 (depends on 1)

The method of claim 1, wherein the taxane particles have a mean particle size (number) of between 0.4 μm and 3 μm.

### Claim 4 (depends on 1)

The method of claim 1, wherein the taxane particles have a mean particle size (number) of between about 0.4 μm and about 1.2 km.

### Claim 5 (depends on 1)

The method of claim 1, wherein the taxane particles have a specific surface area (SSA) of at least 18 m2/g.

### Claim 6 (depends on 1)

The method of claim 1, wherein the suspension further comprises:
a polysorbate, wherein the polysorbate is present in the suspension at a concentration of between about 0.01% v/v and about 1.5% v/v.

### Claim 7 (depends on 1)

The method of claim 1, wherein the pharmaceutically acceptable carrier is saline.

### Claim 8 (depends on 6)

The method of claim 6, wherein the polysorbate is polysorbate 80.

### Claim 9 (depends on 1)

The method of claim 1, wherein the taxane is present in the suspension at a concentration between about 1 mg/ml and about 40 mg/ml.

### Claim 10 (depends on 1)

The method of claim 1, wherein the taxane particles and suspensions thereof are uncoated and exclude lipids, polymers, proteins, polyethoxylated castor oil, and polyethylene glycol glycerides composed of mono-, di- and triglycerides and mono- and diesters of polyethylene glycol.

### Claim 11 (depends on 1)

The method of claim 1, wherein the taxane comprises paclitaxel, docetaxel, cabazitaxel, or a pharmaceutically acceptable salt thereof.

### Claim 12 (depends on 11)

The method of claim 11, wherein the taxane comprises paclitaxel or a pharmaceutically acceptable salt thereof.

### Claim 13 (depends on 1)

The method of claim 1, wherein the taxane particles have a mean bulk density between about 0.050 g/cm3 and about 0.12 g/cm3.

### Claim 14 (depends on 11)

The method of claim 11, wherein the taxane comprises docetaxel or a pharmaceutically acceptable salt thereof.

### Claim 15

(canceled)

### Claim 16 (depends on 1)

The method of claim 1, wherein the taxane remains detectable in lung tissue of the subject for at least 4 days after the administering.

### Claim 17 (depends on 1)

The method of claim 1, wherein the taxane particles are in crystalline form.

### Claim 18 (depends on 1)

The method of claim 1, wherein the aerosol droplets have a mass median aerodynamic diameter (MMAD) of between about 0.5 μm to about 6 μm diameter.

### Claim 19 (depends on 1)

The method of claim 1, wherein the taxane particles reside at the tumor site after administration of the composition exposing the tumor to the taxane particles for a sustained amount of time sufficient to stimulate the endogenous immune system of the subject resulting in the production of tumoricidal cells and infiltration of the tumoricidal cells into the tumor at a level sufficient to treat the tumor.

### Claim 20 (depends on 19)

The method of claim 19, wherein the sustained amount of time is at least 4 weeks.

### Claim 21 (depends on 19)

The method of claim 19, wherein the tumoricidal cells comprise T-cells, B cells, or natural killer (NK) cells, or combinations thereof.

### Claim 22 (depends on 1)

The method of claim 1, wherein the composition is administered in two or more separate administrations.

### Claim 23 (depends on 22)

The method of claim 22, wherein the composition is administered once a week for at least two weeks.

### Claim 24 (depends on 22)

The method of claim 22, wherein the composition is administered twice a week for at least one week, wherein the two or more separate administrations are separated by at least one day.

### Claim 25 (depends on 1)

The method of claim 1, wherein the treatment of the tumor is elimination of the tumor.
